Simple Cystatin C Formula Compared to Serum Creatinine-Based Formulas for Estimation of Glomerular Filtration Rate in Patients with Mildly to Moderately Impaired Kidney Function

Sebastjan Bevc, Radovan Hojs, Robert Ekart, Maksimiljan Gorenjak, Ludvik Puklavec
Departments of Nephrology and Nuclear Medicine, Clinic of Internal Medicine, and Department of Clinical Chemistry, University Medical Center Maribor, Maribor, Slovenia

Abstract

Background: Serum cystatin C (SCC)-based formulas and the newer creatinine formula (the Chronic Kidney Disease Epidemiology Collaboration formula (CKD-EPI)) were proposed as improved glomerular filtration rate (GFR) markers. The aim of our study was to compare serum creatinine (SCr)-based and SCC-based equations against 51Cr-EDTA clearance in patients with mildly to moderately impaired kidney function.

Methods: 255 adult Caucasian patients with chronic kidney disease (GFR 89–30 ml/min/1.73 m²) were enrolled. In each patient, 51Cr-EDTA clearance, SCr and SCC were determined. GFR was calculated using the Cockcroft-Gault (C&G), Modification of Diet in Renal Disease (MDRD), CKD-EPI formulas and simple cystatin C formula (SCCF) (100/SCC).

Results: The receiver-operating characteristic curve analysis (cut-off for GFR 60 ml/min/1.73 m²) showed that the SCCF had a higher diagnostic accuracy than C&G but not than MDRD or CKD-EPI formulas. The Bland-Altman analysis for the same cut-off value showed that creatinine formulas underestimated and SCCF overestimated the measured GFR. Analysis of ability to correctly predict a patient’s GFR <60 or >60 ml/min/1.73 m² showed the higher ability for the SCCF compared to all creatinine-based formulas. Conclusion: Our results indicate that the SCCF is a reliable marker of GFR and comparable to creatinine formulas including the CKD-EPI formula.

Introduction

Chronic kidney disease (CKD) is an important public health problem. CKD is defined as kidney damage or a glomerular filtration rate (GFR) <60 ml/min/1.73 m² for 3 months or more, irrespective of cause, and is classified into stages according to the level of GFR. Therefore, GFR estimation is essential for the evaluation of patients with CKD. GFR estimation allows us to detect early impairment of kidney function, prevent further deterioration and complications, to correct the dosage of drugs cleared by the kidney so as to avoid potential drug toxicity and to help us to manage CKD patients. The National Kidney Disease Education Program (NKDEP) recommended reporting GFR values >60 ml/min/1.73 m² not as an exact
number but simply as >60 ml/min/1.73 m², and contrary for the values of 60 ml/min/1.73 m² and below the exact numerical estimate should be reported [1]. For clinicians the GFR <60 ml/min/1.73 m² is very important. The values indicate the presence of CKD and represent an increased risk of impaired kidney function, progression to kidney failure and premature death caused by cardiovascular events of CKD patients [2, 3].

Over the last decades several different markers for GFR estimation have been proposed. The ideal marker of GFR should be an endogenous molecule which, being produced at a constant rate, is cleared solely by the kidneys via free glomerular filtration, without being either secreted by tubular cells or reabsorbed into peritubular circulation [4]. The ‘gold standard’ for GFR estimation is clearance of exogenous substances such as iohexol, ⁵¹Cr-EDTA, ⁹⁹mTc-DTPA or ¹²⁵I-iothalamate. These techniques are time-consuming, labor-intensive, and expensive and require administration of substances that make them incompatible with routine monitoring.

Despite all known disadvantages, serum creatinine (SCr) concentration has become the most commonly used marker to estimate GFR in clinical practice as in most studies [5]. The current Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines emphasize the need to assess kidney function using predictive equations, such as the Cockcroft-Gault (C&G) formula and abbreviated Modification of Diet in Renal Disease (MDRD) formula, rather than just SCr [6, 7]. Unfortunately, all these formulas are also limited by lack of validation in the full range of GFR to which they are applied [8]. To minimize some of these limitations, such as imprecision and systematic underestimation of the measured GFR with MDRD formula, the new Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI formula) was developed [9]. The authors of the new equation validated the CKD-EPI equation using data pooled from several previous studies and showed that the new formula is more accurate than the widely used MDRD formula [9]. Common features of these equations are reliance on SCr and demographic and anthropometric data, and the accuracy of these formulas is still debated [6, 8].

Recently, serum cystatin C (SCC) was proposed as a new endogenous marker of GFR. This protease inhibitor with a low molecular weight is produced at a constant rate by all nucleated cells. It is freely filtered across the glomerular membrane and is reabsorbed and metabolized in the proximal tubule [10, 11]. The previous reports have suggested that a SCC concentration is a better indicator of GFR than a SCr concentration in patients with spine injury, liver cirrhosis, diabetes, mildly to moderately impaired kidney function, and in elderly patients [12–14]. Over the last few years, several SCC-based equations (cystatin C formulas) have been developed and proposed to estimate the GFR from SCC concentration as an alternative filtration marker to SCr-based equations [15–21].

The aim of our study was to compare three SCr-based equations (C&G, MDRD and CKD-EPI formulas) and the simple cystatin C equation against ⁵¹Cr-EDTA clearance in a population of patients with mildly to moderately impaired kidney function.

## Patients and Methods

In this study, 255 adult Caucasian patients (118 women and 137 men) with mildly to moderately impaired kidney function were included. All patients were referred for ⁵¹Cr-EDTA clearance by nephrologists, diabetologists, cardiologists or general internists because of suspected or established renal dysfunction. At the same time as ⁵¹Cr-EDTA clearance was estimated, both SCr and SCC were measured. SCr was measured by using the kinetic method according to the Jaffe method without deproteinization (isotope dilution mass spectrometry traceable creatinine assay) (Roche Diagnostics). This is a compensated method based on the manufacturer’s instructions and was described previously [22]. SCC was measured by the particle-enhanced immunonephelometric method (Dade Behring). The GFR was estimated from a single ⁵¹Cr-EDTA injection and three blood samples (120, 180 and 240 min after parenteral application of the marker) according to the Committee on Renal Clearance Recommendations [23]. At the time of blood sample collection there were no clinically relevant signs of inflammation observed in the enrolled patients.

⁵¹Cr-EDTA clearance was calculated in milliliters per minute per 1.73 m². The GFR was calculated according to C&G (I), MDRD (II) and CKD-EPI (III) formulas:

I. GFR calculated according to the C&G formula:

\[
\text{GFR} = \frac{140 \text{ (age(years))} \times \text{body weight (kg)}}{[0.815 \times \text{SCr (µmol/l)}]}
\]

The correction factor of 0.85 was used for women.

II. GFR calculated according to the MDRD formula:

\[
\text{GFR} = \frac{175 \times \text{SCr (mg/dl)}^{-1.154} \times \text{age (years)}^{-0.203}}{1.21}
\]

The correction factor of 0.742 was used for women.

III. GFR calculated according to the CKD-EPI formula:

\[
\text{GFR} = a \times \left(\frac{\text{SCr (mg/dl)}}{b}\right)^c \times (0.993)^{\text{age}}
\]

The variable \(a\) takes on the following values on the basis of race and sex:

- Black women = 166; black men = 164; white/other women = 144; white/other men = 141.

The variable \(b\) takes on the following values on the basis of sex:

- Women = 0.7; men = 0.9.

The variable \(c\) takes on the following values on the basis of sex and creatinine measurement:

- Women: SCr ≤ 0.7 mg/dl = –0.329; SCr > 0.7 mg/dl = –1.209,
- Men: SCr ≤ 0.7 mg/dl = –0.411; SCr > 0.7 mg/dl = –1.209.
The C&G formula was standardized for a 1.73-m² body surface area (according to the DuBois & DuBois method). The MDRD formula and CKD-EPI formulas are already standardized for a 1.73-m² body surface area.

GFR was also calculated according to a previously published simple cystatin C formula (SCCF) (IV) [24]:

IV. GFR calculated according to the SCCF: 100/SCC (mg/l).

For statistical analysis, SPSS for Windows (version 12.0.1) and MedCalc for Windows (version 5.00.020) were used. The mean values, range and SD were calculated. Pearson’s correlation coefficient was used for defining the correlation between ⁵¹Cr-EDTA clearance and Scr, SCC, the GFR calculated from the Scr-based formula and the GFR calculated from the cystatin C formula. In order to determine the diagnostic accuracy of the SCC-based formula in comparison with the other markers of GFR, receiver-operating characteristic (ROC) plots were constructed and analyzed. The area under the curve describes the test’s overall performance and is used to compare different tests. Sensitivity and specificity were calculated. The GFR determined with ⁵¹Cr-EDTA was used as the gold standard and the cut-off value for GFR 60 ml/min/1.73 m² of calculated clearance from the C&G, MDRD and CKD-EPI formulas and SCCF was found (p = 0.2401 for the MDRD formula and p = 0.0031 for the CKD-EPI formula). No difference between correlation coefficients of the MDRD or CKD-EPI formulas and SCCF was found (p = 0.2401 and p = 0.2312). Diagnostic accuracy (area under the ROC curves, sensitivity, specificity) and comparison of ROC curves at a cut-off value for GFR 60 ml/min/1.73 m² of calculated clearance from the C&G, MDRD and CKD-EPI formulas and SCCF were presented in table 1. The ROC curve analysis (cut-off for GFR 60 ml/min/1.73 m²) showed that the SCCF had a significantly higher diagnostic accuracy than the C&G formula (p < 0.0001) (table 2; fig. 1). No difference in diagnostic accuracy was found between the SCCF and MDRD (p = 0.376) or CKD-EPI formulas.

**Table 1. Patients’ baseline characteristics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mean ± SD</th>
<th>Median</th>
<th>Range</th>
<th>p value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of cases</td>
<td>255</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males/females</td>
<td>137/118</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean age ± SD, years</td>
<td>59.7 ± 14.1</td>
<td>59</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean body mass index ± SD</td>
<td>27.6 ± 4.7</td>
<td>27</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes patients, n (%)</td>
<td>32 (12.5)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean Scr ± SD, μmol/l</td>
<td>148.1 ± 58</td>
<td>148</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean SCC ± SD, mg/l</td>
<td>1.73 ± 0.7</td>
<td>1.73</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Calculated according to the SCCF.

**Table 2. Diagnostic accuracy (area under the ROC curves, sensitivity, specificity) and comparison of ROC curves at a cut-off value for GFR 60 ml/min/1.73 m² of calculated clearance from the C&G, MDRD and CKD-EPI formulas and SCCF**

<table>
<thead>
<tr>
<th>Equation</th>
<th>AUC</th>
<th>Sensitivity, %</th>
<th>Specificity, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>C&amp;G formula</td>
<td>0.795</td>
<td>69.5</td>
<td>80.8</td>
</tr>
<tr>
<td>MDRD formula</td>
<td>0.890</td>
<td>82.8</td>
<td>85.6</td>
</tr>
<tr>
<td>CKD-EPI formula</td>
<td>0.890</td>
<td>84.1</td>
<td>84.6</td>
</tr>
<tr>
<td>SCCF</td>
<td>0.911</td>
<td>80.8</td>
<td>88.5</td>
</tr>
</tbody>
</table>

GFR determined with ⁵¹Cr-EDTA was used as the gold standard.

Results

The baseline characteristics of the patients studied are presented in table 1. The age of patients ranged from 18 to 86 years (mean 59.7 ± 14.1), heights ranged from 142 to 187 cm (mean 168.5 ± 14.7), mean weight was 78.3 ± 14.7 kg (range 46–142), and mean body mass index was 27.6 ± 4.7 kg/m² (women 26.8 ± 5.2, men 28.2 ± 4.1). Diabetes was present in 12.5% of patients (n = 32). The mean ⁵¹Cr-EDTA clearance in our patients was 55.5 ml/min/1.73 m². The mean Scr concentration value was 148.1 μmol/l (61–651 μmol/l; SD ±58). The SCC concentration values were between 0.59 and 5.37 mg/l (mean 1.73 mg/l; SD ±0.7). A statistically significant correlation was found between ⁵¹Cr-EDTA clearance and SCC (r = –0.665; p < 0.0001), Scr (r = –0.516; p < 0.0001) and with GFR calculated from the C&G formula (r = 0.554; p < 0.0001), the MDRD formula (r = 0.711; p < 0.0001), the CKD-EPI formula (r = 0.710; p < 0.0001), and the SCCF (r = 0.759; p < 0.0001). In a comparison of the correlation coefficients, we found that the correlations between ⁵¹Cr-EDTA clearance and SCCF and ⁵¹Cr-EDTA clearance and the MDRD formula or the CKD-EPI formula and ⁵¹Cr-EDTA clearance were superior to the correlation between ⁵¹Cr-EDTA clearance and the C&G formula (p = 0.00001 for SCCF, p = 0.0029 for the MDRD formula and p = 0.0031 for the CKD-EPI formula). No difference between correlation coefficients of the MDRD or CKD-EPI formulas and SCCF was found (p = 0.2401 and p = 0.2312). Diagnostic accuracy (area under the ROC curves, sensitivity and specificity) at the cut-off value for GFR 60 ml/min/1.73 m² of the different creatinine-based equations and the simple cystatin C-based equation are presented in table 2. The ROC curve analysis (cut-off for GFR 60 ml/min/1.73 m²) showed that the SCCF had a significantly higher diagnostic accuracy than the C&G formula (p < 0.0001) (table 2; fig. 1). No difference in diagnostic accuracy was found between the SCCF and MDRD (p = 0.376) or CKD-EPI formulas.
The Bland-Altman analysis for the same cut-off value showed that creatinine formulas (C&G formula bias: –2.7 ml/min/1.73 m²; MDRD formula bias: –23.2 ml/min/1.73 m²; CKD-EPI formula –19.9 ml/min/1.73 m²) underestimated and the SCCF (bias: 9.0 ml/min/1.73 m²) overestimated the measured GFR. Analysis of the SD of the mean difference between the estimated and measured GFR showed that all equations lacked precision. It was 23.6, 11.6 and 12.7 ml/min/1.73 m² for the C&G, MDRD and CKD-EPI formulas and 17.6 ml/min/1.73 m² for SCCF (Table 3).

The accuracy within 30% of estimated ⁵¹Cr-EDTA clearance values differ according to stages of CKD (Table 4). In patients with mildly impaired kidney function a statistically significant higher accuracy within 30% was found for SCCF (83.7%) compared to accuracy for MDRD (51%) or the CKD-EPI formula (48.1%) (p < 0.0005). On the contrary, in patients with moderately impaired kidney function a statistically significant higher accuracy within 30% was found for the MDRD formula (78.1%) or the CKD-EPI formula (74.8%) compared to accuracy for SCCF (53.6%) (p < 0.0005).

Analysis of ability to correctly predict a patient’s GFR <60 or >60 ml/min/1.73 m² showed the higher ability for SCCF compared to all creatinine-based formulas, and the differences were statistically significant for the MDRD formula (p < 0.0005) or the CKD-EPI formula (p < 0.0027), but not for the C&G formula (p = 0.1512) (Table 3).

### Discussion

The current guidelines emphasize the need to assess kidney function using the predictive creatinine-based equations rather than just SCr [6]. The C&G and MDRD formulas have been evaluated in numerous previously published studies. The formulas have been widely applied, but some studies reported limitations [3]. Therefore, a new creatinine-based CKD-EPI equation was developed [9]. Recently, some new cystatin C formulas were also developed, compared with creatinine formulas and proposed as an alternative filtration marker to creatinine [16, 17, 20, 21, 26, 27]. In our study, we compared all three

![Fig. 1. ROC curve analysis of diagnostic accuracy of calculated clearance from the C&G, MDRD and CKD-EPI formulas and SCCF. The GFR determined with ⁵¹Cr-EDTA was used as the gold standard and the cut-off value was set at 60 ml/min/1.73 m².](image-url)
widely used creatinine-based equations and one very simple cystatin C-based equation in well-defined patients with mildly to moderately impaired kidney function. We have shown that the SCCF achieved at least as good a diagnostic performance as the creatinine formulas, including a newer CKD-EPI formula. Some other studies on populations with CKD showed a higher accuracy of the cystatin C formulas compared to the C&G and MDRD formulas [16, 17]. Some authors even concluded that the cystatin C formula is complementary to the SCr-based equations or can be used in place of the SCr-based equations [20, 21]. Levey et al. [9] showed that the CKD-EPI creatinine-based equation is more accurate than the MDRD study equation across various study populations and clinical conditions, but no such data are available for the CKD-EPI formula compared to SCC-based equations. In our present study in a population of patients with mildly to moderately impaired kidney function, the correlation between the 'gold standard', 51Cr-EDTA clearance and the SCCF was better than the correlation between the 52Cr-EDTA clearance and GFR calculated with the C&G formula. No difference between correlation coefficients of the MDRD formula or the CKD-EPI formula and the SCCF was found. According to our results, the SCCF had a significantly higher diagnostic accuracy for a clinically important cut-off value for GFR 60 ml/min/1.73 m² than the C&G formula. No difference in diagnostic accuracy between the SCCF and creatinine clearance calculated from the MDRD or CKD-EPI formulas was found. The Bland-Altman analysis for the same cut-off value showed that all three creatinine-based formulas underestimated the measured GFR (51Cr-EDTA clearance). On the contrary, the SCCF overestimated the measured GFR. The accuracy within 30% of the estimated gold standard values demonstrated SCCF's superiority compared to the MDRD and CKD-EPI formulas only in patients with mildly impaired kidney function. Furthermore, in the analysis of the ability to correctly predict a patient's GFR <60 or >60 ml/min/1.73 m², the higher ability for the SCCF compared to all creatinine-based formulas was found.

The results of the present study suggest that the cystatin C-based prediction equation, which requires just one variable (SCC concentration), achieved a diagnostic performance that was at least as good as the creatinine formulas using more variables. In our well-defined patients with CKD stage 2–3, the SCCF had a higher diagnostic accuracy in distinguishing patients with mildly to moderately impaired kidney function than the calculated clearance from the C&G formula. The newest sophisti-

cated CKD-EPI formula, like C&G and MDRD formulas, requires additional calculator equipment which is superfluous when SCCF is used.

Our study has some potential limitations. First, the results of the present study only analyze a Caucasian population. The creatinine-based equations were developed from studies which involved participants of all races. Thus, a direct comparison of equations can only be performed between the CKD-EPI formula (equation includes a variable on the basis of race) and SCCF. Second, the above-mentioned studies were performed with different GFR references and gold standards. Some authors used 125I-iothalamate [9, 16, 24] and others used iohexol [15, 21] as the 'gold standard' to measure GFR. In our study, 51Cr-EDTA clearance was used for GFR estimation. Therefore, an exact direct comparison between these studies is difficult. Third, in our study the SCC and SCr were measured only once, so we cannot rule out any known intra-patient variability of SCr or SCC concentration which can be present due to production and/or extrarenal elimination. Finally, the cause of kidney damage in patients with CKD stage 2–3 was not analyzed.

In conclusion, our study has demonstrated that SCCF could be a useful tool for evaluation of renal function in patients with mildly to moderately impaired kidney function in daily clinical practice in hospital and especially in outpatients. Despite the advantages of SCCF, cystatin C-based equations cannot completely replace the 'gold standard' for GFR estimation in a population with CKD, but may contribute to a more accurate selection of patients requiring such invasive and costly procedures. Further research is also needed to evaluate the SCCF on other representative samples, in particular elderly persons, patients with diabetic nephropathy, and other non-Caucasian populations.

Acknowledgment

This study was supported by grant L3-0328 from the Slovenian Research Agency (ARRS).

Disclosure Statement

The authors have no conflicts of interest to disclose.
References


